Results 21 to 30 of about 248,205 (145)

Targeting the Ataxia Telangiectasia Mutated-null Phenotype in Chronic Lymphocytic Leukemia with Pro-oxidants [PDF]

, 2015
Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. Hence, p53-independent strategies are required to target
Agathanggelou, A., Coles, Steven, Darley, R.L., Davies, N.J., Fossey, J.S., Hayes, J.D., Hole, P.S., McMahon, M., Moss, P., Oldreive, C.E., Oscier, D., Parry, H., Payne, D.T., Perry, T., Pratt, G., Skowronska, A., Stankovic, T., Stewart, G., Taylor, M., Wei, W., Weston, V.J.   +20 more
core   +4 more sources

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

New England Journal of Medicine, 2013
BACKGROUND The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey A Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien   +20 more
semanticscholar   +1 more source

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia [PDF]

, 2014
Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action is still undefined, but includes modulation of the microenvironment.
Audrito, V, BULGARELLI, Jenny, COLACI, ELISABETTA, Deaglio, S, FIORCARI, STEFANIA, LUPPI, Mario, MAFFEI, Rossana, MARASCA, Roberto, MARTINELLI, Silvia, NARNI, Franco, POTENZA, Leonardo, ZUCCHINI, Patrizia   +11 more
core   +2 more sources

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax [PDF]

, 2018
Fluorizoline is a new synthetic molecule that induces apoptosis by selectively targeting prohibitins. In the study herein, the pro-apoptotic effect of fluorizoline was assessed in 34 primary samples from patients with chronic lymphocytic leukemia ...
Albericio Palomera, Fernando, Banda, Esmeralda de la, Cosialls Castel, Ana Mª, Gil i Santano, Joan, González Barca, Eva, González Gironés, Diana M., Iglesias i Serret, Daniel, Lavilla Grífols, Rodolfo, Núñez-Vázquez, Sonia, Pomares, Helena, Pons i Irazazábal, Gabriel, Preciado Gallego, Sara, Saura-Esteller, José   +12 more
core   +1 more source

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Leukemia, 2021
Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic ...
W. Wierda, A. Rawstron, F. Cymbalista, X. Badoux, D. Rossi, Jennifer R. Brown, A. Egle, V. Abello, E. Cervera Ceballos, Y. Herishanu, S. Mulligan, C. Niemann, C. Diong, T. Soysal, R. Suzuki, H. Tran, Shang-Ju Wu, C. Owen, S. Stilgenbauer, P. Ghia, P. Hillmen   +20 more
semanticscholar   +1 more source

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2016
BACKGROUND New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of ...
A. Roberts, M. Davids, J. Pagel, B. Kahl, S. Puvvada, J. Gerecitano, T. Kipps, M. Anderson, Jennifer R. Brown, Lori A. Gressick, S. Wong, M. Dunbar, Ming Zhu, Monali Desai, E. Cerri, Sari Heitner Enschede, R. Humerickhouse, W. Wierda, J. Seymour   +18 more
semanticscholar   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Blood, 2008
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, K. Rai, T. Kipps   +10 more
semanticscholar   +1 more source

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +3 more sources

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease [PDF]

, 2014
© 2014 John Wiley & Sons Ltd. Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed the ability of high-resolution single telomere length analysis (STELA), combined with an experimentally ...
Allan, James M., Allsup, David J., Bailey, James, Baird, Duncan M., Britt-Compton, Bethan, Cawkwell, Lynn, Fegan, Chris, Grimstead, Julia W., Heppel, Nicole H., Hills, Robert, Jones, Rhiannon E., Lin, Thet Thet, Norris, Kevin, Pepper, Chris, Pratt, Guy   +14 more
core   +1 more source